Abstract
Vascular complications are a leading cause of blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. There is a growing body of evidence that formation and accumulation of advanced glycation end products (AGEs) progress during normal aging, and at an extremely accelerated rate in diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Furthermore, the interaction by AGEs of their receptor, RAGE, activates down-stream signaling and evokes inflammatory responses in vascular wall cells. Therefore, inhibition of AGE formation or blockade of the RAGE signaling may be a promising target for therapeutic intervention to prevent diabetic vascular complications. This review discusses the molecular mechanisms of diabetic retinopathy, especially focusing on the AGE-RAGE system. Several types of inhibitors of the AGE-RAGE system and their therapeutic implications are also reviewed here.
Keywords: Diabetic retinopathy, advanced glycation end products (AGEs), oxidative stress, receptor for advanced, glycation end products, pigment epithelium-derived factor (PEDF)
Current Drug Discovery Technologies
Title: Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Volume: 3 Issue: 1
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura and Takanori Matsui
Affiliation:
Keywords: Diabetic retinopathy, advanced glycation end products (AGEs), oxidative stress, receptor for advanced, glycation end products, pigment epithelium-derived factor (PEDF)
Abstract: Vascular complications are a leading cause of blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. There is a growing body of evidence that formation and accumulation of advanced glycation end products (AGEs) progress during normal aging, and at an extremely accelerated rate in diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Furthermore, the interaction by AGEs of their receptor, RAGE, activates down-stream signaling and evokes inflammatory responses in vascular wall cells. Therefore, inhibition of AGE formation or blockade of the RAGE signaling may be a promising target for therapeutic intervention to prevent diabetic vascular complications. This review discusses the molecular mechanisms of diabetic retinopathy, especially focusing on the AGE-RAGE system. Several types of inhibitors of the AGE-RAGE system and their therapeutic implications are also reviewed here.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo and Matsui Takanori, Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy, Current Drug Discovery Technologies 2006; 3 (1) . https://dx.doi.org/10.2174/157016306776637555
DOI https://dx.doi.org/10.2174/157016306776637555 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NO to Breast: When, Why and Why Not?
Current Pharmaceutical Design Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science Apoptosis: Its Functions and Control in the Ocular Lens
Current Molecular Medicine Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Possible Role of DNA Methylation in the Induction of Systemic Lupus Erythematosus
Current Rheumatology Reviews SUBJECT INDEX TO VOLUME 1
Current Pharmaceutical Biotechnology Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Proteasomes as Drug Targets
Current Drug Targets